ImaginAb and Lundbeck to Collaborate in Neurodegeneration

          ImaginAb and Lundbeck to Collaborate in Neurodegeneration

Collaboration around CNS imaging with biologics

PR Newswire

LOS ANGELES, Oct. 8, 2012

LOS ANGELES, Oct. 8, 2012 /PRNewswire/ -- ImaginAb, Inc., a clinical-stage
company developing in vivo molecular imaging agents based on antibody fragment
technology, today announced that it has entered into a collaboration and
commercialization agreement with H. Lundbeck A/S. Under the terms of the
agreement, ImaginAb and Lundbeck will collaborate around a novel central
nervous system (CNS) target in order to explore the use of re-engineered
antibodies to accelerate the blood-brain barrier (BBB) transport of biologics.

"This collaboration represents a great opportunity for both companies to
explore an increasingly important intersection between therapeutic and
diagnostic medicine," said Dr.ChristianBehrenbruch, Chief Executive Officer
of ImaginAb. "Given the worrying number of recent failures of late-stage
biologics programs, including for neurodegenerative applications, there is a
critical need to explore new ways of integrating diagnostic and therapeutic
strategies to de-risk development."

Under the terms of the agreement, the parties will collaborate to concurrently
develop biologics with improved BBB transport and imaging agents that are
capable of quantitating kinetics and targeting efficacy. The agreement also
includes an option for Lundbeck to commercialize the results of the
collaboration for both diagnostic and therapeutic uses.

"Molecular imaging has become a prevalent aspect of developing new CNS
products, both during product development and for clinical management of
disease, and we are pleased to be working with ImaginAb to explore this
exciting opportunity," commented Dr.JeffreyStavenhagen, Head of Biologics
for Lundbeck.

About ImaginAb

ImaginAb is redefining therapeutic management by harnessing the power of
antibody technology for in vivo imaging. The company's proprietary antibody
fragment platform yields actionable molecular information to guide treatment
decisions in cancer and immunology.ImaginAb also collaborates with select
biopharmaceutical partners to design imaging agents as companion diagnostics
for therapeutic antibodies. ImaginAb's technology is positioned to deliver on
the promise of personalized medicine by improving patient outcomes and
reducing the cost of healthcare.

For more information, visit www.imaginab.com.

About Lundbeck

H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is an international pharmaceutical
company highly committed to improving the quality of life for people suffering
from brain disorders. For this purpose, Lundbeck is engaged in the research,
development, production, marketing and sale of pharmaceuticals across the
world. The company's products are targeted at disorders such as depression and
anxiety, psychotic disorders, epilepsy and Huntington's, Alzheimer's and
Parkinson's diseases.

Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark. Today
Lundbeck employs approximately 6,000 people worldwide. Lundbeck is one of the
world's leading pharmaceutical companies working with brain disorders. In
2011, the company's revenue was DKK 16.0 billion (approximately EUR 2.1
billion or USD 3.0 billion). For more information, please visit
www.lundbeck.com.

SOURCE ImaginAb, Inc.

Website: http://www.imaginab.com
Contact: Chris Erdman, MacDougall Biomedical Communications, +1-781-235-3060,
cerdman@macbiocom.com